Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape


Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine. Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been unsuccessful1,2,3, a minority of individuals naturally develop these antibodies after many years of infection4,5,6,7. How such antibodies arise, and the role of viral evolution in shaping these responses, is unknown. Here we show, in two HIV-1–infected individuals who developed BCN antibodies targeting the glycan at Asn332 on the gp120 envelope, that this glycan was absent on the initial infecting virus. However, this BCN epitope evolved within 6 months, through immune escape from earlier strain-specific antibodies that resulted in a shift of a glycan to position 332. Both viruses that lacked the glycan at amino acid 332 were resistant to the Asn332-dependent BCN monoclonal antibody PGT128 (ref. 8), whereas escaped variants that acquired this glycan were sensitive. Analysis of large sequence and neutralization data sets showed the 332 glycan to be significantly under-represented in transmitted subtype C viruses compared to chronic viruses, with the absence of this glycan corresponding with resistance to PGT128. These findings highlight the dynamic interplay between early antibodies and viral escape in driving the evolution of conserved BCN antibody epitopes.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Characterizing the antibody specificities and viral populations in CAP177 and CAP314.
Figure 2: The glycan at position 332 mediates neutralization escape in CAP177 and CAP314.
Figure 3: The glycan at residue 332 is underrepresented in subtype C transmitted/founder viruses, which are also frequently resistant to the PGT128 mAb.


  1. 1

    Haynes, B.F. & Montefiori, D.C. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5, 347–363 (2006).

    CAS  Article  Google Scholar 

  2. 2

    Hu, S.L. & Stamatatos, L. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5, 507–513 (2007).

    CAS  Article  Google Scholar 

  3. 3

    Phogat, S. & Wyatt, R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13, 213–227 (2007).

    CAS  Article  Google Scholar 

  4. 4

    Li, Y. et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1–infected individuals. J. Virol. 83, 1045–1059 (2009).

    CAS  Article  Google Scholar 

  5. 5

    Sather, D.N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757–769 (2009).

    CAS  Article  Google Scholar 

  6. 6

    Simek, M.D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337–7348 (2009).

    CAS  Article  Google Scholar 

  7. 7

    Stamatatos, L., Morris, L., Burton, D.R. & Mascola, J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15, 866–870 (2009).

    CAS  Article  Google Scholar 

  8. 8

    Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011).

    CAS  Article  Google Scholar 

  9. 9

    Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144–4149 (2003).

    CAS  Article  Google Scholar 

  10. 10

    Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003).

    CAS  Article  Google Scholar 

  11. 11

    Frost, S.D. et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. USA 102, 18514–18519 (2005).

    CAS  Article  Google Scholar 

  12. 12

    Gray, E.S. et al. Antibody specificities associated with neutralization breadth in plasma from HIV-1 subtype C infected blood donors. J. Virol. 83, 8925–8937 (2009).

    CAS  Article  Google Scholar 

  13. 13

    Tomaras, G.D. et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1–infected individuals. J. Virol. 85, 11502–11519 (2011).

    CAS  Article  Google Scholar 

  14. 14

    Walker, L.M. et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6, e1001028 (2010).

    Article  Google Scholar 

  15. 15

    Gray, E.S. et al. HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828–4840 (2011).

    CAS  Article  Google Scholar 

  16. 16

    Nandi, A. et al. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396, 339–348 (2010).

    CAS  Article  Google Scholar 

  17. 17

    Tang, H. et al. epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B–infected individuals. J. Virol. 85, 9286–9299 (2011).

    CAS  Article  Google Scholar 

  18. 18

    Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009).

    CAS  Article  Google Scholar 

  19. 19

    Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097–1103 (2011).

    CAS  Article  Google Scholar 

  20. 20

    Abrahams, M.R. et al. Quantitating the multiplicity of infection with HIV-1 subtype C reveals a non-Poisson distribution of transmitted variants. J. Virol. 83, 3556–3567 (2009).

    CAS  Article  Google Scholar 

  21. 21

    Moore, P.L. et al. The C3–V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J. Virol. 82, 1860–1869 (2008).

    CAS  Article  Google Scholar 

  22. 22

    Moore, P.L. et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5, e1000598 (2009).

    Article  Google Scholar 

  23. 23

    Gray, E.S., Moore, P.L., Pantophlet, R.A. & Morris, L. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J. Virol. 81, 10769–10776 (2007).

    CAS  Article  Google Scholar 

  24. 24

    Binley, J.M. et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78, 13232–13252 (2004).

    CAS  Article  Google Scholar 

  25. 25

    Bures, R. et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J. Virol. 76, 2233–2244 (2002).

    CAS  Article  Google Scholar 

  26. 26

    Gray, E.S., Meyers, T., Gray, G., Montefiori, D.C. & Morris, L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 3, e255 (2006).

    Article  Google Scholar 

  27. 27

    Zhang, M. et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14, 1229–1246 (2004).

    CAS  Article  Google Scholar 

  28. 28

    Gnanakaran, S. et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 7, e1002209 (2011).

    CAS  Article  Google Scholar 

  29. 29

    Bunnik, E.M. et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 16, 995–997 (2010).

    CAS  Article  Google Scholar 

  30. 30

    Salazar-Gonzalez, J.F. et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 82, 3952–3970 (2008).

    CAS  Article  Google Scholar 

  31. 31

    Gorny, M.K. & Zolla-Pazner, S. Immunoprophylaxis against mother-to-child transmission of HIV-1. PLoS Med. 3, e259 (2006).

    Article  Google Scholar 

  32. 32

    Walker, L.M. et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl. Acad. Sci. USA 108, 20125–20129 (2011).

    CAS  Article  Google Scholar 

  33. 33

    van Loggerenberg, F. et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS ONE 3, e1954 (2008).

    Article  Google Scholar 

  34. 34

    Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168–1174 (2010).

    CAS  Article  Google Scholar 

  35. 35

    Gao, F. et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J. Virol. 70, 1651–1667 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36

    Gray, E.S. et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81, 6187–6196 (2007).

    CAS  Article  Google Scholar 

Download references


We thank the participants in the CAPRISA 002 and 004 cohorts and the clinical and laboratory staff at CAPRISA for managing the cohort and providing specimens. 293T cells were obtained from G. Shaw (University of Alabama, Birmingham). We are grateful to D. Burton and W. Koff of the International AIDS Vaccine Initiative for providing the PGT monoclonal antibodies and to S. Gnanakaran (Los Alamos National Laboratories, Los Alamos, New Mexico) for providing transmitted/founder and chronic subtype B sequences. We thank Z. Valley-Omar and N. Ndabambi for generating some envelope sequences. We are grateful to B. Hahn and J. Kim, who contributed transmitted/founder subtype C clones to the Vaccine Immune Monitoring Core Standard Virus Panel Consortium. This work was funded by CAPRISA, the Centre for HIV/AIDS Vaccine Immunology, the South African HIV/AIDS Research and Innovation Platform of the South African Department of Science and Technology and by a US National Institutes of Health grant (number AI088610). CAPRISA was initially supported by the US National Institute of Allergy and Infectious Diseases, US National Institutes of Health, US Department of Health and Human Services grant U19 AI51794. M.S.S. is funded by the Bill & Melinda Gates Foundation, Vaccine Immune Monitoring Consortium of the Collaboration for AIDS Vaccine Discovery (grant 1032144). P.L.M. and E.S.G. were supported by the Columbia University-Southern African Fogarty AIDS International Training and Research Program through the Fogarty International Center, National Institutes of Health (grant 5 D43 TW000231). P.L.M. is a Wellcome Trust Intermediate Fellow in Public Health and Tropical Medicine (grant 089933/Z/09/Z).

Author information




P.L.M. and E.S.G. designed the study, performed experiments, analyzed data and wrote the manuscript; E.S.G., C.K.W., J.N.B., T.H. and N.L.T. performed neutralization experiments and analyzed data; E.S.G., C.K.W., D.J.S., M.N., B.E.L. and N.R. generated single-genome sequences; D.J.S. and N.N. performed part of the sequence analyses; M.-R.A., L.P., R.I.S. and C.W. contributed the subtype C acute and chronic sequences; S.B. and M.S.S. designed and performed the neutralization experiments using the panel of transmitted/founder viruses; S.S.A.K., Q.A.K. and C.W. established the CAPRISA cohorts and contributed samples and data for these subjects; and L.M. designed the study and wrote the manuscript.

Corresponding author

Correspondence to Lynn Morris.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–6 (PDF 1306 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moore, P., Gray, E., Wibmer, C. et al. Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18, 1688–1692 (2012).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing